Rare Hereditary Gynecological Cancer Syndromes
- PMID: 35163487
- PMCID: PMC8835983
- DOI: 10.3390/ijms23031563
Rare Hereditary Gynecological Cancer Syndromes
Abstract
Hereditary cancer syndromes, which are characterized by onset at an early age and an increased risk of developing certain tumors, are caused by germline pathogenic variants in tumor suppressor genes and are mostly inherited in an autosomal dominant manner. Therefore, hereditary cancer syndromes have been used as powerful models to identify and characterize susceptibility genes associated with cancer. Furthermore, clarification of the association between genotypes and phenotypes in one disease has provided insights into the etiology of other seemingly different diseases. Molecular genetic discoveries from the study of hereditary cancer syndrome have not only changed the methods of diagnosis and management, but have also shed light on the molecular regulatory pathways that are important in the development and treatment of sporadic tumors. The main cancer susceptibility syndromes that involve gynecologic cancers include hereditary breast and ovarian cancer syndrome as well as Lynch syndrome. However, in addition to these two hereditary cancer syndromes, there are several other hereditary syndromes associated with gynecologic cancers. In the present review, we provide an overview of the clinical features, and discuss the molecular genetics, of four rare hereditary gynecological cancer syndromes; Cowden syndrome, Peutz-Jeghers syndrome, DICER1 syndrome and rhabdoid tumor predisposition syndrome 2.
Keywords: Cowden syndrome; DICER1 syndrome; Peutz–Jeghers syndrome; molecular genetics; rare hereditary gynecological cancer; rhabdoid tumor predisposition syndrome 2.
Conflict of interest statement
The authors declare no conflict of interest.
Similar articles
-
Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation.Pathology. 2018 Feb;50(2):238-256. doi: 10.1016/j.pathol.2017.10.009. Epub 2018 Jan 17. Pathology. 2018. PMID: 29373116 Review.
-
Hereditary gynecologic tumors and precision cancer medicine.J Obstet Gynaecol Res. 2022 May;48(5):1076-1090. doi: 10.1111/jog.15197. Epub 2022 Feb 28. J Obstet Gynaecol Res. 2022. PMID: 35229413 Review.
-
Gynecological lesions in hereditary cancer predisposition syndromes.Cesk Patol. 2021 Summer;57(2):96-104. Cesk Patol. 2021. PMID: 34275319 Review. English.
-
BRCA and Beyond: Comprehensive Image-rich Review of Hereditary Breast and Gynecologic Cancer Syndromes.Radiographics. 2020 Mar-Apr;40(2):306-325. doi: 10.1148/rg.2020190084. Epub 2020 Feb 7. Radiographics. 2020. PMID: 32031911 Review.
-
Hereditary Cancer Syndromes and Risk Assessment: ACOG COMMITTEE OPINION SUMMARY, Number 793.Obstet Gynecol. 2019 Dec;134(6):1366-1367. doi: 10.1097/AOG.0000000000003563. Obstet Gynecol. 2019. PMID: 31764755
Cited by
-
Outcomes and the effect of PGT-M in women with hormone-related hereditary tumor syndrome.Front Oncol. 2024 May 10;14:1378019. doi: 10.3389/fonc.2024.1378019. eCollection 2024. Front Oncol. 2024. PMID: 38800375 Free PMC article.
-
Moderate-Risk Genes for Hereditary Ovarian Cancers Involved in the Homologous Recombination Repair Pathway.Int J Mol Sci. 2022 Oct 4;23(19):11790. doi: 10.3390/ijms231911790. Int J Mol Sci. 2022. PMID: 36233090 Free PMC article. Review.
-
Co-Occurrence of Germline Genomic Variants and Copy Number Variations in Hereditary Breast and Colorectal Cancer Patients.Genes (Basel). 2023 Aug 3;14(8):1580. doi: 10.3390/genes14081580. Genes (Basel). 2023. PMID: 37628631 Free PMC article.
-
A Novel Pathogenic Variant of DICER1 Gene in a Young Greek Patient with 2 Different Sex-Cord Ovarian Tumors and Multinodular Goiter.Int J Mol Sci. 2025 Feb 25;26(5):1990. doi: 10.3390/ijms26051990. Int J Mol Sci. 2025. PMID: 40076617 Free PMC article.
-
DICER1-related Sertoli-Leydig cell tumor and rhabdomyosarcoma: An evolving disease with a challenging clinical course and treatment: A case report.Case Rep Womens Health. 2024 Jan 6;41:e00580. doi: 10.1016/j.crwh.2024.e00580. eCollection 2024 Mar. Case Rep Womens Health. 2024. PMID: 38282900 Free PMC article.
References
-
- Paluch-Shimon S., Cardoso F., Sessa C., Balmana J., Cardoso M.J., Gilbert F., Senkus E. ESMO Guidelines Committee. Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO Clinical Practice Guidelines for cancer prevention and screening. Ann. Oncol. 2016;27((Suppl. S5)):v103–v110. doi: 10.1093/annonc/mdw327. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources